Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 25 January 2026 - 31 January 2026

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson shares rose 0.4% to $221.01 Monday as investors awaited the Federal Reserve’s Jan. 28 decision and major tech earnings. The company projected 2026 adjusted earnings per share of $11.43–$11.63 and sales up to $101 billion. A court-appointed special master recommended allowing expert testimony that J&J’s talc caused ovarian cancer, raising the risk of federal trials. J&J denies the allegations.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson shares rose 0.76% to $220.14 at Friday’s close, outpacing other major pharma stocks. The company reaffirmed its 2026 sales and profit targets after posting Q4 sales of $24.6 billion and adjusted EPS of $2.46. Legal risks remain as a special master recommended expert testimony in federal talc lawsuits. Investors await the Federal Reserve’s rate decision on Wednesday.
25 January 2026
··
1 2 3 4 … 11

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop